Atlas Trials

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

Clinical trial NCT01807221 · COMPLETED

Trial details

NCT number
NCT01807221
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Heart Failure
Start date
2013-06-17
Primary completion
2014-11-11
Enrollment
1066

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.